Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.35 |
| ▸ | HASPIN | Q8TF76 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2807459 | 0.77 | ADRB2 (0.41) | MCHR1KDM4ESPRADRB2 | |
| SCHEMBL13132433 | 0.76 | ADRB2 (0.40) | MCHR1KDM4ESPRADRB2 | |
| SCHEMBL2806731 | 0.70 | ITK (0.40) | KDM4E | |
| SCHEMBL10740599 | 0.65 | ADRB2 (0.53) | HASPINKDM4ESPRADRB2 | |
| SCHEMBL2548825 | 0.65 | GPR84 (0.57) | MCHR1KDM4E | |
| SCHEMBL10747217 | 0.62 | KDM4E (0.43) | KDM4E | |
| SCHEMBL13132253 | 0.62 | REN (0.40) | PARP1 | |
| SCHEMBL23545640 | 0.62 | ALDH1A1 (0.51) | PARP1KDM4E | |
| SCHEMBL23917680 | 0.62 | MAPT (0.49) | KDM4ESPRADRB2 | |
| SCHEMBL8124376 | 0.61 | BRD4 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| EP-2168952-A1 | MORPHOLINE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | REN, AGTR1, AGTR2 | PARP1 3636/4885MCHR1 613/4885HASPIN 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.